Symbols

HRTX

Heron Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Strong Buy"

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HRTX

Heron Therapeutics, Inc.

A commercial-stage biotechnology company that develops therapeutics used in nausea and vomiting prevention, pain management, and to treat inflammation

Industry

Pharmaceutical

Established Date

Listing Date

01/23/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

128

Fiscal Year Ends

12-31

Website

www.herontx.com

Security Type

Common stock

Office address

100 Regency Forest Drive, Suite 300, Cary, North Carolina 27518

Business

Introduction

Heron Therapeutics, Inc., was incorporated in California in February 1983 and re-registered in Delaware in 1987. The company is a commercialization stage biotechnology company dedicated to the development and commercialization of innovative therapeutic products for acute care and oncology patients. Its emergency care portfolio includes ZYNRELEF, a double-acting local anesthetic for postoperative pain, and APONVIE, an intravenous preparation for postoperative nausea and vomiting.

Company Financials

EPS

HRTX has released its 2025 Q4 earnings. EPS was reported at -0.02, versus the expected -0.02, meeting expectations. The chart below visualizes how HRTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

HRTX has released its 2025 Q4 earnings report, with revenue of 40.59M, reflecting a YoY change of -0.47%, and net profit of -2.95M, showing a YoY change of -180.64%. The Sankey diagram below clearly presents HRTX's revenue sources and cost distribution.